BCEL Atreca Inc.

14.91
+0.32  (+2%)
Previous Close 14.59
Open 14.75
52 Week Low 9.51
52 Week High 29.35
Market Cap $537,198,458
Shares 36,029,407
Float 21,331,902
Enterprise Value $382,180,047
Volume 1,511,130
Av. Daily Volume 374,234
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ATRC-101
Solid tumors
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020
    Wednesday, September 16, 2020
    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020
    Thursday, September 17, 2020
    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at…

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020

    Wednesday, September 16, 2020

    Presentation time: 3:30 p.m. EDT

    Morgan Stanley Virtual Global Healthcare Conference 2020

    Thursday, September 17, 2020

    Presentation time: 3:30 p.m. EDT

    A live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of each webcast will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390



    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase…

    SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent developments.

    "The second quarter was eventful for Atreca as we continue to execute on our various development objectives," said John Orwin, Chief Executive Officer. "We recently presented preclinical data for ATRC-101 demonstrating that its novel target is induced by chemotherapeutics and further validating its novel mechanism of action. Our Phase 1b first-in-human study evaluating ATRC-101 continues to enroll patients and now has five trial sites active. In addition, our recently announced strategic collaboration with Xencor to develop bispecific T cell-engaging antibodies underscores the value of novel targets in oncology and the ability of our technology platform to attract weaponization partners. We believe these milestones, coupled with our strengthened financial position from the completion an equity financing in July, position us well for continued progress in the second half of 2020."

    Recent Developments and Highlights

    • A Phase 1b first-in-human study evaluating ATRC-101 in patients with select solid tumor cancers is ongoing. Screening continues in the study and patients are currently being enrolled in the second dose cohort. To date, five clinical trial sites have been activated. Atreca expects to announce initial safety data from the study in late 2020 or early 2021. In addition to monotherapy expansion cohorts, clinical trials of ATRC-101 in combination with a PD-1 inhibitor and in combination with a chemotherapeutic are planned for 2021.

       
    • Atreca hosted a webinar in June to present new preclinical data regarding the novel target and mechanism of action of ATRC-101, demonstrating both innate and adaptive immune system activation and target induction via chemotherapy.

       
    • Atreca entered into a strategic collaboration and license agreement with Xencor, Inc. to research, develop and commercialize T cell-engaging bispecific antibodies as potential therapeutics in oncology. Under a three-year discovery program, Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. Up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits. Atreca and Xencor may also pursue up to two programs independently, with a mid-to high-single digit percent royalty payable on net sales.

       
    • Atreca strengthened its financial position with the completion of a public equity offering in July 2020, resulting in net proceeds of approximately $117.5 million.

       
    • Atreca appointed Ms. Kristine M. Ball to the Company's board of directors. Ms. Ball brings more than 25 years of life sciences industry experience focused primarily on finance, corporate development and strategic planning.

       
    • Atreca continues to collaborate with BeiGene, and IGM Biosciences on a potential novel antibody treatment for COVID-19.

    Second Quarter 2020 Financial Results

    • As of June 30, 2020, cash, cash equivalents and investments totaled $148.8 million. In addition, Atreca completed a public equity offering in July 2020 resulting in net proceeds of approximately $117.5 million, and after deducting the underwriting discounts and commissions and estimated offering expenses.

       
    • Research and development expenses for the three months ended June 30, 2020 were $14.2 million, including non-cash share-based compensation expense of $1.8 million.

       
    • General and administrative expenses for the three months ended June 30, 2020 were $6.5 million, including non-cash share-based compensation expense of $1.6 million.

       
    • Atreca reported a net loss of $20.0 million, or basic and diluted net loss per share attributable to common stockholders of $0.71, for the three months ended June 30, 2020.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Forward-Looking Statements

    This release contains forward-looking statements regarding our strategy and future plans, including statements regarding the development of ATRC-101 and our clinical and regulatory plans, and the timing thereof. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "will", "believe," "potential," "continue," "expects," "planned," "may," and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

    Atreca, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share and per share data)

          
     June 30,  December 31,  
     2020  2019 
          
    ASSETS     
          
    Current Assets
    Cash and cash equivalents$  100,430  $  157,954 
    Investments  43,088    14,663 
    Prepaid expenses and other current assets  5,112    3,502 
    Total current assets  148,630    176,119 
    Property and equipment, net  7,666    5,771 
    Long-term investments  5,311    10,799 
    Deposits and other  2,934    3,026 
    Total assets$  164,541  $  195,715 
          
    LIABILITIES AND STOCKHOLDERS' EQUITY
          
    Current Liabilities
    Accounts payable $  1,060  $  2,133 
    Accrued expenses  4,434    5,395 
    Other current liabilities  1,859    419 
    Total current liabilities  7,353    7,947 
    Capital lease obligations, net of current portion  29    53 
    Deferred rent  2,887    763 
    Other non-current liabilities  157    -  
    Total liabilities  10,426    8,763 
          
          
    Stockholders' equity
    Common stock  3    3 
    Additional paid-in capital  358,401    351,039 
    Accumulated other comprehensive income  216    16 
    Accumulated deficit  (204,505)   (164,106)
    Total stockholders' equity   154,115    186,952 
    Total liabilities and stockholders' equity $  164,541  $  195,715 
          



    Atreca, Inc.

    Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

    (unaudited)

    ($ amounts in 000's, except per share amounts)           
                 
      Three Months Ended

      Six Months Ended

     
      June 30,

      June 30,

     
      2020  2019  2020  2019 
    Expenses           
     Research and development$  14,180  $  15,922  $  28,390  $  27,635 
     General and administrative  6,458    3,537    13,581    6,055 
     Total expenses  20,638    19,459    41,971    33,690 
    Interest and other income (expense)           
     Other income  403    1,021    634    1,186 
     Interest income  255    594    940    1,139 
     Interest expense  (1)   (2)   (2)   (4)
     Preferred stock warrant liability revaluation  —     (73)   —     (123)
     Loss on disposal of property and equipment  —     (2)   —     (7)
    Loss before Income tax expense  (19,981)   (17,921)   (40,399)   (31,499)
    Income tax expense  -     -     -     (1) 
    Net loss$  (19,981) $  (17,921) $  (40,399) $  (31,500)
    Net loss per share, basic and diluted$  (0.71) $  (3.67) $  (1.44) $  (8.97)
    Weighted-average shares used in computing            
    net loss per share, basic and diluted  28,144,714    4,888,987    28,082,930    3,512,606 
                 



    Contacts



    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    2020 Wedbush PacGrow Healthcare Virtual Conference
    Wednesday, August 12, 2020
    Presentation time: 2:20 p.m. EDT

    Canaccord Genuity 40th Annual Growth Conference
    Thursday, August 13, 2020
    Presentation time: 4:00 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will…

    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in two upcoming investor conferences:

    2020 Wedbush PacGrow Healthcare Virtual Conference

    Wednesday, August 12, 2020

    Presentation time: 2:20 p.m. EDT

    Canaccord Genuity 40th Annual Growth Conference

    Thursday, August 13, 2020

    Presentation time: 4:00 p.m. EDT

    Live webcasts of each event can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. Archived replays of the webcasts will be available on the Company's website for 90 days following the live presentations.

    About Atreca, Inc.

    Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

    Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer

    Investors:

    Alex Gray, 650-779-9251, ext. 251

    Media:

    Sheryl Seapy, 213-262-9390

    Source: Atreca, Inc.

    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the "Shares"), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Atreca has granted the underwriters a 30-day option to purchase…

    SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the "Shares"), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Atreca has granted the underwriters a 30-day option to purchase up to 1,171,875 additional shares of its Class A Common Stock at the public offering price, less underwriting discounts and commissions.  The offering is expected to close on or about July 20, 2020, subject to the satisfaction of customary closing conditions. All of the shares are being offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as lead manager for the offering. Roth Capital Partners, LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-managers for the offering.

    A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus.  Copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, by email at or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by email at , or by telephone at (888) 474-0200; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Atreca's expectations regarding the completion and timing of the public offering. In some cases, you can identify these statements by forward-looking words such as "expect," "will," "may," or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Atreca's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering. There can be no assurance that Atreca will be able to complete the public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Atreca's periodic filings with the SEC, including under the heading "Risk Factors" contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Atreca makes in this press release speak only as of the date of this press release. Except as required by law, Atreca assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    Atreca Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Primary Logo

    View Full Article Hide Full Article
  5. REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of its Class A Common Stock (the "Shares") in an underwritten public offering. In connection with the offering, Atreca expects to grant the underwriters a 30-day option to purchase additional shares of its Class A Common Stock.  All of the Shares will be offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. The offering is subject…

    REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (NASDAQ:BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced that it intends to offer shares of its Class A Common Stock (the "Shares") in an underwritten public offering. In connection with the offering, Atreca expects to grant the underwriters a 30-day option to purchase additional shares of its Class A Common Stock.  All of the Shares will be offered by Atreca.

    Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

    A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. Prospective investors should read the preliminary prospectus supplement, when available, and the accompanying prospectus and other documents we have filed with the SEC for more complete information about us and the offering. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by email at or by telephone at (833) 297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by email at , or by telephone at (888) 474-0200; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Atreca's expectations regarding the completion, timing and size of the proposed public offering. In some cases, you can identify these statements by forward-looking words such as "expect," "may," "will,"  or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Atreca's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Atreca will be able to complete the proposed public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Atreca's periodic filings with the SEC, including under the heading "Risk Factors" contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Atreca makes in this press release speak only as of the date of this press release. Except as required by law, Atreca assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    Atreca Contacts

    Atreca, Inc.

    Herb Cross

    Chief Financial Officer





    Investors:

    Alex Gray, 650-779-9251

    Media:

    Sheryl Seapy, 213-262-9390

    Primary Logo

    View Full Article Hide Full Article
View All Atreca Inc. News